Replies to post #247604 on Biotech Values

[dewophile]

There are some companies that rely heavily on a small number of products for revenue where there are fewer moving parts. Regeneron is a prime example. Maybe it’s because eyelea is a part B drug amd that doesn’t go into effect until 2026??